First human test of new inflammation blocker halted early
NCT ID NCT05740280
Summary
This was the first-ever study in people for a new experimental drug called iCP-NI, designed to block inflammation. The main goal was to check if the drug was safe and how the body processes it in 24 healthy volunteers. The study was terminated early, and no results on how well it works for treating diseases are available.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Labcorp Clinical Research Unit Inc.
Daytona Beach, Florida, 32117, United States
Conditions
Explore the condition pages connected to this study.